Quarterly ResultMay 5, 2026, 04:12 PM
Carlsmed Q1 Revenue $16.1M, +58% YoY; Raises FY26 Guidance
AI Summary
Carlsmed, Inc. reported strong first-quarter 2026 financial results, with revenue growing 58.2% year-over-year to $16.1 million. The company also raised its full-year 2026 revenue guidance to a range of $72 million to $77 million. Despite an increased net loss of ($8.7) million, Carlsmed highlighted significant business achievements, including positive clinical data for its aprevo® implants and the debut of its corra™ personalized cervical plating system.
Key Highlights
- Q1 2026 revenue reached $16.1 million, a 58.2% increase year-over-year.
- Full-year 2026 revenue guidance raised to $72 million to $77 million.
- Q1 2026 gross profit was $12.4 million, with a gross margin of 77.1%.
- Q1 2026 net loss was ($8.7) million, compared to ($5.7) million in Q1 2025.
- A study published in Global Spine Journal demonstrated a 74% reduction in reoperations for aprevo® lumbar implants.
- Performed first procedure using the corra™ personalized cervical plating system in February.
- Cash and cash equivalents, restricted cash, and short-term investments totaled $97.1 million.